"A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer" by R. J. Kelly

Article

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer

Annals of Oncology (2013)

R. J. Kelly, Johns Hopkins University
A. Thomas, 2Medical Oncology Branch, Center for Cancer Research
A. Rajan, 2Medical Oncology Branch, Center for Cancer Research
G. Chun, 2Medical Oncology Branch, Center for Cancer Research
A. Lopez-Chavez, 2Medical Oncology Branch, Center for Cancer Research
E. Szabo, National Institutes of Health
S. Spencer, 2Medical Oncology Branch, Center for Cancer Research
C. A. Carter, Walter Reed National Military Medical Center
U. Guha, 2Medical Oncology Branch, Center for Cancer Research
S. Khozin, 2Medical Oncology Branch, Center for Cancer Research
S. Poondru, Center for Global Development
C. Van Sant, Center for Global Development
A. Keating, Center for Global Development
S. M. Steinberg, National Institutes of Health
W. Figg, 2Medical Oncology Branch, Center for Cancer Research
G. Giaccone, 2Medical Oncology Branch, Center for Cancer Research

Link

Disciplines

Publication Date

January 10, 2013

DOI

10.1093/annonc/mdt249

Citation Information

R. J. Kelly, A. Thomas, A. Rajan, G. Chun, et al.. "A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer" Annals of Oncology Vol. 24 Iss. 10 (2013) p. 2601 - 2606
Available at: http://works.bepress.com/shawn-spencer/6/